↓ Skip to main content

Dove Medical Press

Article Metrics

Bevacizumab for glioblastoma

Overview of attention for article published in Therapeutics and Clinical Risk Management, December 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (76th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
4 tweeters
patent
1 patent

Citations

dimensions_citation
31 Dimensions

Readers on

mendeley
67 Mendeley
Title
Bevacizumab for glioblastoma
Published in
Therapeutics and Clinical Risk Management, December 2015
DOI 10.2147/tcrm.s58289
Pubmed ID
Authors

Yoshitaka Narita

Abstract

Individuals with glioblastoma are often characterized by older age, advanced neurologic manifestations at the primary stage, and unresectable tumors, and these factors are associated with poor treatment outcomes. Administration of bevacizumab (BV, Avastin(®)) promotes tumor regression and improves cerebral edema, and is expected to improve neurologic findings in many patients with malignant gliomas, including glioblastoma. Although the addition of BV to the conventional standard therapy (chemoradiotherapy with temozolomide) for newly diagnosed glioblastoma prolonged the progression-free survival time and the performance status of patients, it failed to extend overall survival time. However, more than 50% of glioblastoma patients show Karnofsky performance status ≤70 at initial presentation; therefore, BV should be used to improve or maintain their performance status as an initial treatment. Most of the adverse events of BV, except hypertension and proteinuria, occur as complications of glioblastoma, and explanation of the advantages and disadvantages of BV administration to patients is important. Herein, the efficacy, safety, and challenges of using BV for treating glioblastoma were reviewed.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 1%
Turkey 1 1%
Unknown 65 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 15 22%
Student > Ph. D. Student 14 21%
Student > Master 10 15%
Researcher 6 9%
Other 6 9%
Other 9 13%
Unknown 7 10%
Readers by discipline Count As %
Medicine and Dentistry 21 31%
Agricultural and Biological Sciences 10 15%
Biochemistry, Genetics and Molecular Biology 6 9%
Immunology and Microbiology 4 6%
Nursing and Health Professions 3 4%
Other 16 24%
Unknown 7 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2017.
All research outputs
#4,282,326
of 17,366,233 outputs
Outputs from Therapeutics and Clinical Risk Management
#187
of 1,100 outputs
Outputs of similar age
#85,583
of 373,221 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#8
of 50 outputs
Altmetric has tracked 17,366,233 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,100 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 373,221 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 76% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.